NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 264 filers reported holding NOVOCURE LTD in Q2 2020. The put-call ratio across all filers is 1.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | – | 19 | 0.0% | 0.00% | – |
| Q2 2023 | $0 | -100.0% | 19 | -98.2% | 0.00% | – |
| Q1 2023 | $62 | -18.4% | 1,046 | 0.0% | 0.00% | – |
| Q4 2022 | $76 | -99.9% | 1,046 | 0.0% | 0.00% | – |
| Q3 2022 | $79,000 | – | 1,046 | +12975.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 8 | -99.4% | 0.00% | – |
| Q1 2022 | $111,000 | +192.1% | 1,350 | +166.3% | 0.00% | – |
| Q4 2021 | $38,000 | -97.8% | 507 | -96.7% | 0.00% | -100.0% |
| Q3 2021 | $1,760,000 | +993.2% | 15,166 | +1989.0% | 0.00% | – |
| Q2 2021 | $161,000 | +46.4% | 726 | -13.4% | 0.00% | – |
| Q1 2021 | $110,000 | -34.1% | 838 | -13.6% | 0.00% | – |
| Q4 2020 | $167,000 | -18.5% | 970 | -47.5% | 0.00% | – |
| Q3 2020 | $205,000 | +60.2% | 1,847 | -14.9% | 0.00% | – |
| Q2 2020 | $128,000 | -28.5% | 2,170 | -18.8% | 0.00% | – |
| Q1 2020 | $179,000 | +265.3% | 2,672 | +350.6% | 0.00% | – |
| Q4 2019 | $49,000 | +11.4% | 593 | 0.0% | 0.00% | – |
| Q3 2019 | $44,000 | -83.8% | 593 | -95.6% | 0.00% | – |
| Q4 2017 | $271,000 | – | 13,425 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |